Filing Details

Accession Number:
0001415889-22-012194
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-07 20:52:34
Reporting Period:
2022-12-05
Accepted Time:
2022-12-07 20:52:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1597264 Blueprint Medicines Corp BPMC Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1638474 W. Jeffrey Albers C/O Blueprint Medicines Corporation
45 Sidney Street
Cambridge MA 02139
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-12-05 10,000 $1.87 193,243 No 4 M Direct
Common Stock Acquisiton 2022-12-05 10,000 $15.01 203,243 No 4 M Direct
Common Stock Disposition 2022-12-05 20,000 $50.09 183,243 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2022-12-05 10,000 $0.00 10,000 $1.87
Common Stock Stock Option (Right to Buy) Disposition 2022-12-05 10,000 $0.00 10,000 $15.01
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
95,073 2024-07-30 No 4 M Direct
20,000 2026-02-03 No 4 M Direct
Footnotes
  1. Effected pursuant to a trading plan adopted on January 11, 2022 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $50.00 to $50.45 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. This option was granted on July 30, 2014 and is fully vested as of the date hereof.
  4. This option was granted on February 3, 2016 and is fully vested as of the date hereof.